Alasdair J Coles

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. doi request reprint New treatment strategies in multiple sclerosis
    Joanne L Jones
    Dept of Clinical Neurosciences, Box 165 Addenbrooke s Hospital, Hills Road, Cambridge, CB2 0QQ, UK
    Exp Neurol 225:34-9. 2010
  2. ncbi request reprint Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
    Joanne L Jones
    Department of Clinical Neuroscience, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 0QQ, UK
    Brain 133:2232-47. 2010
  3. ncbi request reprint Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
    Alasdair J Coles
    Department of Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Lancet Neurol 10:338-48. 2011
  4. pmc Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
    J William L Brown
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Drug Des Devel Ther 7:131-8. 2013
  5. ncbi request reprint Alemtuzumab treatment of multiple sclerosis
    Alasdair J Coles
    Department of Clinical Neurosciences, Addenbrooke s Hospital, University of Cambridge, Cambridge, England, United Kingdom
    Semin Neurol 33:66-73. 2013
  6. pmc Alemtuzumab therapy for multiple sclerosis
    Alasdair J Coles
    Department of Clinical Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge, CB2 0QQ, UK
    Neurotherapeutics 10:29-33. 2013
  7. doi request reprint Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
    Alasdair J Coles
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Lancet 380:1829-39. 2012
  8. doi request reprint Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial
    A J Coles
    Department of Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge UK
    Neurology 78:1069-78. 2012
  9. ncbi request reprint Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells
    Alasdair J Coles
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Eur J Immunol 35:3694-703. 2005
  10. ncbi request reprint The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy
    Alasdair J Coles
    Department of Clinical Neurosciences, Box 165, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    J Neurol 253:98-108. 2006

Collaborators

Detail Information

Publications23

  1. doi request reprint New treatment strategies in multiple sclerosis
    Joanne L Jones
    Dept of Clinical Neurosciences, Box 165 Addenbrooke s Hospital, Hills Road, Cambridge, CB2 0QQ, UK
    Exp Neurol 225:34-9. 2010
    ..In this review, we first sketch the landscape of novel therapies in multiple sclerosis and then discuss in detail approaches which are likely to emerge over the next few years...
  2. ncbi request reprint Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity
    Joanne L Jones
    Department of Clinical Neuroscience, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge, CB2 0QQ, UK
    Brain 133:2232-47. 2010
    ....
  3. ncbi request reprint Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes
    Alasdair J Coles
    Department of Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Lancet Neurol 10:338-48. 2011
    ..Additionally, we aimed to describe a new outcome measure in multiple sclerosis research: sustained reduction in disability...
  4. pmc Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
    J William L Brown
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Drug Des Devel Ther 7:131-8. 2013
    ..Alemtuzumab has been submitted for licensing in relapsing-remitting multiple sclerosis in the United States and Europe...
  5. ncbi request reprint Alemtuzumab treatment of multiple sclerosis
    Alasdair J Coles
    Department of Clinical Neurosciences, Addenbrooke s Hospital, University of Cambridge, Cambridge, England, United Kingdom
    Semin Neurol 33:66-73. 2013
    ..Its use requires careful monitoring so that potentially serious side effects can be treated early and effectively...
  6. pmc Alemtuzumab therapy for multiple sclerosis
    Alasdair J Coles
    Department of Clinical Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge, CB2 0QQ, UK
    Neurotherapeutics 10:29-33. 2013
    ..Its use requires careful monitoring so that potentially serious side effects can be treated early and effectively...
  7. doi request reprint Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
    Alasdair J Coles
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Lancet 380:1829-39. 2012
    ..We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment...
  8. doi request reprint Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial
    A J Coles
    Department of Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge UK
    Neurology 78:1069-78. 2012
    ....
  9. ncbi request reprint Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4+CD25hi and CD4+FoxP3+) T cells
    Alasdair J Coles
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Eur J Immunol 35:3694-703. 2005
    ....
  10. ncbi request reprint The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy
    Alasdair J Coles
    Department of Clinical Neurosciences, Box 165, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    J Neurol 253:98-108. 2006
    ..These concepts are currently being tested in a controlled trial comparing Campath-1H and IFN-beta in the treatment of drug-naïve patients with early, active RR MS...
  11. pmc Unilateral calf hypertrophy
    A Coles
    Department of Neurology, Box 165, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    J Neurol Neurosurg Psychiatry 75:1606. 2004
  12. ncbi request reprint Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench
    Alasdair Coles
    Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 2QQ, UK
    Clin Neurol Neurosurg 106:270-4. 2004
  13. pmc Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
    Joanne L Jones
    Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0QQ, United Kingdom
    Proc Natl Acad Sci U S A 110:20200-5. 2013
    ..Taken together, these findings demonstrate that homeostatic proliferation drives lymphopenia-associated autoimmunity in humans. ..
  14. pmc IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
    Joanne L Jones
    Department of Clinical Neuroscience, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Clin Invest 119:2052-61. 2009
    ..We propose that, by driving cycles of T cell expansion and apoptosis to excess, IL-21 increases the stochastic opportunities for T cells to encounter self antigen and, hence, for autoimmunity...
  15. doi request reprint B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis
    Sara A J Thompson
    Department of Clinical Neurosciences, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    J Clin Immunol 30:99-105. 2010
    ..Alemtuzumab (previously called Campath 1-H) induces a prolonged T-cell lymphopenia with memory cells dominating the reconstituting T-cell pool for at least 3 months...
  16. ncbi request reprint Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
    Amanda L Cox
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Eur J Immunol 35:3332-42. 2005
    ..We speculate that CCL21 and IL-15 responses to lymphopaenia may be suboptimal in multiple sclerosis...
  17. ncbi request reprint Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis
    Laura Azzopardi
    Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK
    J Neurol Neurosurg Psychiatry 85:795-8. 2014
    ..Here we ask whether currently available ELISAs have similar prognostic value...
  18. ncbi request reprint Campath-1H treatment of multiple sclerosis
    Joanne L Jones
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Neurodegener Dis 5:27-31. 2008
    ..Here, we summarise our clinical and laboratory findings, describing how this prototypical 'bench to bedside' therapy continues to inform basic science, revealing aspects of the pathogenesis of multiple sclerosis and autoimmunity...
  19. pmc Immune competence after alemtuzumab treatment of multiple sclerosis
    Claire L McCarthy
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
    Neurology 81:872-6. 2013
    ..To determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab...
  20. ncbi request reprint Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis
    J William L Brown
    Department of Clinical Neurosciences, Addenbrooke s Hospital, University of Cambridge, United Kingdom Electronic address
    J Neuroimmunol 271:66-8. 2014
    ..Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides...
  21. doi request reprint Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
    Grant A Hill-Cawthorne
    Department of Neurology, University of Cambridge, Cambridge, UK
    J Neurol Neurosurg Psychiatry 83:298-304. 2012
    ..The long term effects on lymphocyte reconstitution of a single course, and the consequences that this has on disability, morbidity, mortality and autoimmunity, were examined...
  22. pmc Notes on the kidney and its diseases for the neurologist
    Michael S Zandi
    Department of Clinical Neurosciences, University of Cambridge, Box 165, Addenbrooke s Hospital, Cambridge, UK
    J Neurol Neurosurg Psychiatry 78:444-9. 2007
    ..We consider the current evolving trial evidence that directs the usage of a growing arsenal of therapies in the induction and maintenance stages of vasculitis treatment, and extend this consideration to Lupus and Sjogren's...
  23. pmc No association between multiple sclerosis and the Notch3 gene responsible for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
    S A Broadley
    University of Cambridge Neurology Unit, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ, UK
    J Neurol Neurosurg Psychiatry 71:97-9. 2001
    ..No evidence for association was found in any of the three markers and none of the commoner mutations causing CADASIL were found in the sequenced patients...